IP Library › Granted Patent US 10,442,851
Granted Patent B2
US 10,442,851 · App. 15/127,166 · Granted Oct 15, 2019

Serum albumin-binding fibronectin type III domains

Inventors: Tracy S. Mitchell (Andover, MA); Michael L. Gosselin (Boston, MA); Dasa Lipovsek (Cambridge, MA); Rex Parker (Titusville, NJ); Ray Camphausen (Wayland, MA); Jonathan Davis (Auburndale, MA); David Fabrizio (South Hamilton, MA)
Assignee: BRISTOL-MYERS SQUIBB COMPANY
C07K14/78A61K47/64A61K38/00C07K2319/00C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,442,851
App. No.
15/127,166
Granted
Oct 15, 2019
Kind
B2
Abstract

The present invention relates to polypeptides which include tenth fibronectin type III domains ( 10 Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10 Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Claims (12)

1. A polypeptide comprising a fibronectin type III tenth domain ( 10 Fn3) wherein the amino acid sequence of the CD loop of the wild-type 10 Fn3 domain set forth in SEQ ID NO: 1 is replaced by an amino acid sequence selected from the group consisting of SEQ ID NOs: 101-125, and wherein the polypeptide binds to human serum albumin, and to one or more of rhesus serum albumin, cynomolgus serum albumin, mouse serum albumin, and rat serum albumin.

2. The polypeptide of claim 1 , wherein the polypeptide is a fusion polypeptide comprising a heterologous protein.

3. The fusion polypeptide of claim 2 , wherein the heterologous protein is a therapeutic moiety.

4. The fusion polypeptide of claim 2 , wherein the heterologous protein is a polypeptide comprising a 10 Fn3 domain.

5. The fusion polypeptide of claim 4 , wherein the 10 Fn3 domain of the heterologous protein binds to a target protein other than serum albumin.

6. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-30, 32-40, 42-56, 58-66, 68-82, 84-92, 94-100, 184-191, 193-201, 203-209, 235-242, 243-252 and 254-260, wherein the polypeptide binds to human serum albumin, and to one or more of rhesus serum albumin, cynomolgus serum albumin, mouse serum albumin, and rat serum albumin.

7. The polypeptide of claim 6 , wherein the polypeptide is a fusion polypeptide comprising a heterologous protein.

8. The fusion polypeptide of claim 7 , wherein the heterologous protein is a therapeutic moiety.

9. The fusion polypeptide of claim 7 , wherein the heterologous protein is a polypeptide comprising a 10 Fn3 domain.

10. The fusion polypeptide of claim 8 , wherein the 10 Fn3 domain of the heterologous protein binds to a target protein other than serum albumin.

11. A composition comprising the polypeptide of claim 1 and a carrier.

12. A composition comprising the polypeptide of claim 6 and a carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2018
From: MITCHELL, TRACY S.; GOSSELIN, MICHAEL L.; LIPOVSEK, DASA; PARKER, REX; CAMPHAUSEN, RAY; DAVIS, JONATHAN; FABRIZIO, DAVID
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 045589/0030 →
Continuity (2)
Provisional Application 61968181 · Mar 20, 2014
Related Publication 20170174748A1 · Jun 22, 2017
Cited By (1)
US 12,534,511